IARTIntegra LifeSciences Holdings Corporation
$13.44-4.9% 1Y
$13.44
$8.9052 weeks$19.87
The financials
Integra LifeSciences Holdings Corporation by the numbers
Integra LifeSciences Holdings Corporation (IART) reported revenue of $419M in Q2 2026 (quarter ended Jun 30, 2026), up 0.8% from the same quarter a year earlier. That came with a gross margin of 52% and net income of $4.5M (1.1% of revenue). For the full year FY2025, revenue was $1.64B (+1.5% year on year) and net income −$516M. Its largest product in Q2 2026 was Neurosurgery at $213M, 51% of the disclosed total, well ahead of Wound Reconstruction Solutions at 19%. The next results filing is expected around Jan 1, 2027, a quarter after the last one.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $419M | $416M | +0.8% |
| Gross profit | $220M | $209M | +5.0% |
| Operating income | $19M | −$513M | to a profit |
| Net income | $4.5M | −$484M | to a profit |
| Diluted EPS | $0.06 | −$6.31 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Neurosurgery | $213M | 51% |
| Wound Reconstruction Solutions | $81M | 19% |
| Surgical Instruments | $55M | 13% |
| ENT Solutions | $41M | 9.8% |
| Private Label | $28M | 6.7% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $418.8M (+6.8%)
Private Label grew +4.8% year on yearWound Reconstruction Solutions -4.1% year on year
Segment Latestquarter on quarteryear on year
- Neurosurgery$213.3M$213.3Mquarter on quarter +7.6%year on year +2.0%+7.6%+2.0%
- Wound Reconstruction Solutions$81.3M$81.3Mquarter on quarter n/ayear on year -4.1%n/a-4.1%
- Surgical Instruments$54.8M$54.8Mquarter on quarter n/ayear on year +3.3%n/a+3.3%
- ENT Solutions$41.2M$41.2Mquarter on quarter n/ayear on year -1.6%n/a-1.6%
- Private Label$28.2M$28.2Mquarter on quarter -3.3%year on year +4.8%-3.3%+4.8%